SPRY · ARS Pharmaceuticals Inc
United States · RS rating 8 · As of 2026-11-03
| Price | 3.05 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 8 / 13 / 12 / 14 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 19 / 7 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -3.3% |
| Sales growth Q/Q | -13.6% |
| Distance from 52-week high | +76.7% |
| Market cap (USD) | $824.2M |